ClinicalTrials.gg
RecruitingNCT06057714Updated Jul 2, 2026

Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis

An observational study in Cystic Fibrosis and Ventilatory Defect, sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by University of North Carolina, Chapel Hill · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Cystic Fibrosis by University of North Carolina, Chapel Hill — 2 open to participants now, 4 under way, none of them phase 3. Cystic Fibrosis · University of North Carolina, Chapel Hill.

Started
2021
the only one that year
Observational
7 of 20
2 open now
Registered
20th of 20
by date

Among the 20 studies in Cystic Fibrosis by University of North Carolina, Chapel Hill, this one is the only one that started in 2021, is one of 7 observational ones, and was the 20th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 20 studies in Cystic Fibrosis by University of North Carolina, Chapel Hill are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Cystic Fibrosis by University of North Carolina, Chapel Hill, or all of them as a file.
02

Study summary

The purpose of this study is to look at lung ventilation in people with cystic fibrosis over time (1 year) using magnetic resonance imaging (MRI) with an inhaled contrast gas, and compare these measures to lung function assessed by spirometry and multiple breath nitrogen washout. This study also looks at how these measures change in response to a pulmonary exacerbation and treatment (if applicable). Over the span of a year, participants would be asked to complete 3-5 visits to the University of North Carolina at Chapel Hill (UNC). with each lasting up to 4 hours. If participants do not have a pulmonary exacerbation during the year they would be asked to complete 3 visits (one at enrollment, a second roughly 2 weeks later, and the third approximately a year later). If participants do experience a CF pulmonary exacerbation they would complete 5 visits (Visit 1, Visit 2, two exacerbation visits with one before treatment and the other after, and Visit 3 at one year after Visit 1). Only one exacerbation per participant will be tracked. Participants are eligible for this study if they are 18 years old or older, have Cystic Fibrosis (CF) with mild lung disease (FEV1 >/= 60%), and can undergo an MRI. There are no known benefits for participating in this study.

03

Conditions studied

  • Cystic Fibrosis
  • Ventilatory Defect

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with cystic fibrosis and stable lung disease at the time of enrollment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be ≥18 years of age
  2. Non-smokers (\<10 pack/year history and no active smoking in the past year)
  3. Diagnosis of cystic fibrosis via standard sweat chloride/phenotypic features/genotyping
  4. No use of supplemental oxygen
  5. Stable lung function (within 10% of personal best in the last 6 months) with no pulmonary exacerbations in the past 4 weeks and baseline ≥60% of predicted
  6. Evidence of a personally signed and dated consent indicating that the subject has been informed of all pertinent aspects of the trial
  7. Subjects must be willing and able to comply with scheduled visits and other trial procedures

Exclusion criteria

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the trial:

  1. Active or past smokers or vapers with less than 1 year since quitting or >10 pack-year smoking history
  2. Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of including

    1. Occupation (past or present) of machinist, welder, or grinder;
    2. Injury to the eye involving a metallic object
    3. Injury to the body by a metallic object (bullet, bullet ball, shrapnel)
    4. Presence of a cardiac pacemaker or defibrillator
    5. Presence of aneurysm clips
    6. Presence of carotid artery vascular clamp
    7. Presence of neurostimulator
    8. Presence of insulin or infusion pump
    9. Presence of implanted drug infusion device that is not known to be MRI compatible (i.e., was placed outside of UNC or is older than 10 years)
    10. Bone growth or fusion simulator
    11. Presence of cochlear, otologic or ear implant
    12. Any type of prosthesis (eye, penile, etc.)
    13. Artificial limb or joint
    14. Non-removable electrodes (on body, head or brain)
    15. Intravascular stents, filters or coils
    16. Shunt (spinal or intraventricular)
    17. Swan-Ganz catheter
    18. Any implant held in place by a magnet
    19. Transdermal delivery system (e.g. Nitro)
    20. An intrauterine device or diaphragm that is not MRI compatible
    21. Tattooed makeup (eyeliner, lips, etc.) or tattoos covering >25% of body surface area
    22. Body piercings (must be removed before MRI)
    23. Any metal fragments
    24. Internal pacing wires
    25. Metal or wire mesh implants
    26. Hearing aid (remove before MRI) aa. Dentures (remove before MRI) bb. Claustrophobia
  3. Unable to tolerate inhalation of gas mixture
  4. Presence of facial hair that may interfere with the fit of the mask (and unwillingness to shave prior to each MRI)
  5. Any changes in medications that may affect CF lung disease in the past 28 days, including any experimental therapies
  6. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
  7. Pregnancy; women of must have a confirmed negative urine pregnancy test on the day of the MR scan, prior to the MRI scan.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • All Participants

    All subjects to receive inhaled perfluoropropane via standard Douglas bag at every visit (3-5 visits). They will breathe the gas for 5 breath hold cycles (variable volumes as lung capacity/size varies per participant). Not to exceed 30 liters inhaled at each visit as this is the max capacity of our Douglas bag.

    Combination Product: 19F MRI

Interventions

  • Combination product19F MRI

    Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing

    Also known as: Perfluoropropane (PFP)

06

What researchers measure

Primary outcomes

  1. Change in Ventilation Defect Parameter (VDP) over 14 days

    VDP measured at Day 1 and Day 14, expressed as a percentage of total lung volume

    Time frame: Day 1 to Day 14

  2. Change in VDP over 365 days

    Average of VDP measured at Day 1 and Day 14; subtracted from VDP at Day 365, expressed as a percentage of total lung volume

    Time frame: Day 1 to Day 365 (+/- 30 days)

  3. Change in FLVlongtau2 over 14 days

    FLVlongtau2 measured at Day 1 and Day 14, expressed as a percentage of total lung volume

    Time frame: Day 1 to Day 14

  4. Change in FLVlongtau2 over 365 days

    Average of FLVlongtau2 measured at Day 1 and Day 14; subtracted from FLVlongtau2 at Day 365, expressed as a percentage of total lung volume

    Time frame: Day 1 to Day 365 (+/- 30 days)

  5. Change in VDP occurring with a protocol-defined CF pulmonary exacerbation

    Difference in VDP between baseline and exacerbation visit 1, expressed as a percentage of total lung volume.

    Time frame: Day 1 to Day 365 (+/- 30 days)

  6. Change in FLVlongtau2 occurring with a protocol-defined CF pulmonary exacerbation

    Difference in FLVlongtau2 between baseline and exacerbation visit 1, expressed as a percentage of total lung volume.

    Time frame: Day 1 to Day 365 (+/- 30 days)

Secondary outcomes

  1. Change in MRI severity score over 365 days

    Change in MRI severity score from baseline to Day 365.

    Time frame: Day 1 to Day 365 (+/- 30 days)

  2. Correlation of MRI severity score with VDP at baseline.

    Baseline is a mean of the VDP scores from Day 1 and Day 14 (expressed as percentage of lung). Correlation of MRI scores with VDP and FLVlongtau2

    Time frame: Day 1 to Day 14

  3. Correlation of MRI severity score with FLVlongtau2 at baseline.

    Baseline is a mean of the FLVlongtau2 scores from Day 1 and Day 14 (expressed as percentage of lung). Correlation of MRI scores with VDP and FLVlongtau2

    Time frame: Day 1 to Day 14

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2021 (actual). Primary completion is estimated for Aug 2026, 67 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2023
First posted
Sep 28, 2023
StartActual
Jan 20, 2021
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06057714
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Cystic Fibrosis Foundation
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Jan 20, 2021
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jul 2, 2026

Study contacts

Jennifer L Goralski, MD
Contact
jennifer_goralski@med.unc.edu
919-445-0331
Margret Z Powell, BS
Contact
margret_powell@med.unc.edu
984-974-2962
Jennifer L Goralski, MD
principal investigator · UNC Chapel Hill

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion